Amir Kazory,Claudio Ronco
Amir Kazory
This is an overview of some of the impactful studies in the field of cardiorenal medicine that were published in 2024. The Author(s). Published by S. Kar...
Biomarkers for Predicting of Sepsis-Induced Cardiorenal Syndrome in Emergency Settings [0.03%]
生物标志物在急诊科预测脓毒症引起的心肾综合征的作用
Yuanyuan Pei,Liping Guo,Guangping Zhou et al.
Yuanyuan Pei et al.
Introduction: Cardiorenal syndrome (CRS) is a common and critical complication of sepsis, with high morbidity and mortality rates. Studies on biomarkers for the early prediction of septic CRS are sporadic. Classic and nov...
Immunosuppressive therapy-related cardiovascular risk factors in renal transplantation: a narrative review [0.03%]
肾移植中与免疫抑制治疗相关的心血管危险因素：叙述性综述
Chiara Paccagnella,Stefano Andreola,Alessia Gambaro et al.
Chiara Paccagnella et al.
Background: Kidney transplantation is the best treatment for patients with chronic renal failure, capable of improving life expectancy and the risk of death from all causes, which, however, remains higher than in the gene...
HepatoCardioRenal Syndrome: Integrating Pathophysiology with Clinical Decision-Making via POCUS [0.03%]
肝心肾综合征：通过POCUS整合病理生理与临床决策
Abhilash Koratala,Claudio Ronco,Amir Kazory
Abhilash Koratala
Background: Accumulating evidence has challenged the traditional model of the liver-kidney connection in hepatorenal syndrome. Cirrhosis can significantly impact cardiac function, leading to cirrhotic cardiomyopathy. Rece...
A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units [0.03%]
心血管-肾脏综合征管理的新时代：心血管-肾脏单元的重要性
Juan León-Román,María Antonieta Azancot,Catarina Marouco et al.
Juan León-Román et al.
Introduction: Approximately 70% of patients with heart failure (HF) also have kidney disease. Mortality is increased both by cardiorenal syndrome (CRS) and by the exacerbation of other comorbidities. The purpose of this s...
Association of Liver Fibrosis Markers with Mortality Outcomes in Patients with Chronic Kidney Disease and Coronary Artery Disease: Insights from the NHANES 1999-2018 Data [0.03%]
肝纤维化标志物与慢性肾脏病和冠状动脉疾病患者死亡风险的关系：来自NHANES 1999-2018数据的启示
Zixiang Ye,Enmin Xie,Ziyu Guo et al.
Zixiang Ye et al.
Introduction: The objective of this research is to explore the possible link between markers of liver fibrosis and survival rates in a group of adults who have been diagnosed with both chronic kidney disease (CKD) and cor...
EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease (CKD) and Heart Failure [0.03%]
EMCREG慢性肾脏病（CKD）和心力衰竭高钾血症管理国际多学科共识小组
Natalie Kreitzer,Nancy M Albert,Alpesh N Amin et al.
Natalie Kreitzer et al.
Background: Hyperkalemia, generally defined as serum potassium levels greater than 5.0 mEq/L, poses significant clinical risks, including cardiac toxicity and muscle weakness. Its prevalence and severity increase in patie...
Cardiorenal disease and heart failure with preserved ejection fraction: Two sides of the same coin [0.03%]
心肾疾病和射血分数保留型心力衰竭：一枚硬币的两面
Gonzalo Núñez-Marína,Enrique Santas
Gonzalo Núñez-Marína
Background: Heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) have a strong pathophysiological interrelationship, and their combination worsens prognosis. ...
Predicting In-Hospital Mortality in Patients With End-Stage Renal Disease Receiving Extracorporeal Membrane Oxygenation Therapy [0.03%]
血液净化治疗终末期肾病患者的院内死亡预测模型
Tsung-Yu Tsai,Pei-Chun Fan,Cheng-Chia Lee et al.
Tsung-Yu Tsai et al.
Introduction: Patients on extracorporeal membrane oxygenation (ECMO) often experience worse renal outcomes and higher mortality rates as the severity of kidney injury increases. Nevertheless, the in-hospital mortality ris...
Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin Following an Admission for Acute Heart Failure [0.03%]
达格列净治疗急性心力衰竭患者后抗原糖类125的变化趋势分析
Gema Miñana,Rafael de la Espriella,Miguel Lorenzo-Hernández et al.
Gema Miñana et al.
Introduction: Antigen carbohydrate 125 (CA125) has emerged as a proxy of fluid overload and inflammation in acute heart failure (AHF). We aimed to evaluate the influence of dapagliflozin on CA125 levels within the first w...